但讽刺的是，专利战打得火热，商业化却已悄然加速。全球首款CRISPR疗法Casgevy已获批上市，销售额稳步攀升，多家公司在研管线进入晚期临床。专利归属虽悬而未决，但投资人早已用脚投票：CRISPR相关美股公司市值回暖，Cathie Wood（木头姐 ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...

In the late 2010s eight macaque monkeys were born at a laboratory in Shanghai. At first they seemed much like the other infants in the colony, but differences soon became obvious. They were much more ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

CRISPR powers everything from gene editing to rapid diagnostics, but how did one of its most versatile branches arise? A new Cell study, “Functional RNA splitting drove the evolutionary emergence of ...

CRISPR Therapeutics (CRSP) earns a Hold rating as pipeline breadth grows but CASGEVY's launch remains slow and economically unattractive. CRSP’s in vivo editing platform shows strong early validation, ...